More tools:Markets·Screener·Research·Chat

Jaguar Health, Inc. (JAGX) Financial Statements

Jaguar Health, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG005Z205T2
XNAS · usd
0.41▼ 0.18 (-30.60%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close0.60
Day's Range0.40 – 0.51
52-Week Range0.22 – 8.00
Volume944.8K
Avg Volume238.8K
Share Statistics
Shares Outstanding
Employees47
ExchangeXNAS
Listed2015-05-13
Share count as of August 14, 2026
Loading Income Statement…
Key questions about Jaguar Health, Inc. (JAGX)
What is Jaguar Health, Inc.'s Market Cap?
Jaguar Health, Inc.'s Market Cap is $2.1M, based on as-reported figures from SEC (XBRL) filings.
What is Jaguar Health, Inc.'s Price / Sales?
Jaguar Health, Inc.'s Price / Sales is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is Jaguar Health, Inc.'s Revenue (TTM)?
Jaguar Health, Inc.'s Revenue (TTM) is $27.8M, based on as-reported figures from SEC (XBRL) filings.
What is Jaguar Health, Inc.'s Net Income (TTM)?
Jaguar Health, Inc.'s Net Income (TTM) is -$43.1M, based on as-reported figures from SEC (XBRL) filings.
What is Jaguar Health, Inc.'s EBITDA?
Jaguar Health, Inc.'s EBITDA is -$24.0M, based on as-reported figures from SEC (XBRL) filings.
What is Jaguar Health, Inc.'s Diluted EPS (TTM)?
Jaguar Health, Inc.'s Diluted EPS (TTM) is -8.35, based on as-reported figures from SEC (XBRL) filings.
What is Jaguar Health, Inc.'s EBITDA Margin?
Jaguar Health, Inc.'s EBITDA Margin is -86.3%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
Total revenue, net
YoY growth-58.9%+815.6%-7.8%-0.8%
Operating expenses
Cost of product revenue
Research and development
Sales and marketing
General and administrative
Total operating expenses
% of revenue720.2%49.8%756.6%334.8%
Income (loss) from operations
% of revenue-620.2%50.2%-656.6%-234.8%
Loss on extinguishment of debt
Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option
Interest income (expense)
Other income (expense)
Income (loss) before income tax expense
Income tax expense
Net loss before equity in net loss of joint venture———
Net income (loss)
% of revenue-1045.1%43.0%-716.9%-312.9%
Net loss attributable to noncontrolling interest
Stock dividends to preferred stockholders——
Deemed dividend to preferred stockholders——
Cumulative preferred dividends allocated to preferred stockholders———
Net loss attributable to common stockholders
Net loss per share, basic—
Net loss per share, diluted—